NCT03544021 is a Phase 1, PHASE2 clinical trial of CART-19 cells in Leukemia, Lymphocytic, Acute, sponsored by The Affiliated Hospital of the Chinese Academy of Military Medical Sciences.

What drugs are being tested in NCT03544021?

Interventions in NCT03544021: CART-19 cells.

What condition does NCT03544021 study?

NCT03544021 studies Leukemia, Lymphocytic, Acute.

Is NCT03544021 still recruiting?

NCT03544021 is currently status unknown. Last updated 4 June 2018.

Last reviewed 2018-06-04 · How we verify

NCT03544021

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia （ALL）

Status unknown Phase 1, PHASE2 Last updated 4 June 2018

What this trial tests

Phase 1, PHASE2 trial testing CART-19 cells in Leukemia, Lymphocytic, Acute in 10 participants. Status unknown.

Timeline

1 March 2018

Primary endpoint
1 March 2019

1 March 2020

Quick facts

Lead sponsor	The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 March 2018
Primary completion	1 March 2019
Estimated completion	1 March 2020
Sites	1 location across China

Drugs / interventions tested

CART-19 cells — full drug profile →

Conditions studied

Leukemia, Lymphocytic, Acute — all drugs for Leukemia, Lymphocytic, Acute →

Sponsor

The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

Who can join

Adults 14 to 75, any sex, with Leukemia, Lymphocytic, Acute. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and efficiency of CD19-Targeted CAR-T in Treating Patients with relapsed/refractory acute leukemia.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Recent updates on allogeneic CAR-T cells in hematological malignancies.
Mansoori S, Noei A, Maali A, Seyed-Motahari SS, et al · · 2024 · cited 34× · PMID 39227937 · DOI 10.1186/s12935-024-03479-y
The future of cellular immunotherapy for childhood leukemia.
Bonifant CL, Tasian SK. · · 2020 · cited 15× · PMID 31851053 · DOI 10.1097/mop.0000000000000866
Chimeric antigen receptor modified T-cells for cancer treatment.
Han X, Wang Y, Han WD. · · 2018 · cited 11× · PMID 30603741 · DOI 10.1016/j.cdtm.2018.08.002

Verify or expand the search:

Other recruiting trials for Leukemia, Lymphocytic, Acute

Currently open trials in the same condition.

NCT06904066 — Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients W · Phase 1 · recruiting
NCT04988555 — A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) · Phase 1, PHASE2 · recruiting

Other The Affiliated Hospital of the Chinese Academy of Military Medical Sciences trials

Trials by the same sponsor.

NCT07356856 — Efficacy and Safety of Microtransplantation for Advanced and Relapsed Solid Tumors · Phase 1 · not yet recruiting
NCT05095558 — Microtransplantation for Ovarian Cancer · Phase 1, PHASE2 · unknown
NCT04937842 — Microtransplantation for Advanced and Relapsed Solid Tumors · Phase 1, PHASE2 · unknown
NCT04174586 — Cord Blood Microtransplantation for Treatment of Acute Myeloid Leukemia · Phase 1 · unknown
NCT03556982 — CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia（AML） · Phase 1, PHASE2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03544021 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Last refreshed: 4 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03544021.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing